-

GEMINI SPACE STATION, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Gemini Space Station, Inc. (“Gemini” or the “Company”) (NASDAQ:GEMI). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.

[LEARN MORE ABOUT THE INVESTIGATION]

What Happened?

On September 12, 2025, Gemini conducted its initial public offering, selling 15,937,501 shares of Class A common stock priced at $28.00. Then, on February 17, 2026, Gemini disclosed in a filing with the U.S. Securities and Exchange Commission “that it will be parting ways with each of Marshall Beard, Chief Operating Officer, Dan Chen, Chief Financial Officer, and Tyler Meade, Chief Legal Officer, each effective as of February 17, 2026[.]” On this news, the price of Gemini shares declined by $0.97 per share, or approximately 12.83%, from $7.56 per share on February 13, 2026 to close at $6.59 on February 17, 2026.

What Should I Do?

At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.

If you purchased or otherwise acquired Gemini securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
investigations@kmllp.com

Kirby McInerney LLP

NASDAQ:GEMI

Release Versions

Contacts

Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
investigations@kmllp.com

More News From Kirby McInerney LLP

BABA INVESTOR ALERT: Securities Class Action Filed Against Alibaba Group Holding Limited – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Alibaba Group Holding Limited (“Alibaba” or the “Company”) (NYSE: BABA) common stock between June 26, 2025 and June 24, 2026, inclusive (“the Class Period”). If you suffered a loss on your Alibaba investments, you have until October 5, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after...

CASH SHAREHOLDER ALERT: Pathward Financial, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Pathward Financial, Inc. (“Pathward” or the “Company”) (NASDAQ: CASH) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On July 22, 2026, Pathward reported fiscal third-quarter 2026. Among other things, the Company re...

REPL SHAREHOLDER ALERT: Replimune Group Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Replimune Group Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On July 28, 2026, the FDA released briefing documents regarding the Company’s lead trial for its dru...
Back to Newsroom